相关实验视频

Updated: Sep 19, 2025

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

与CyBorD相比,daratumumab-CyBorD的生存率提高,作为AL氨基粉症的前线治疗方法

Binoy Yohannan¹, Matthew Rees¹, Morie A Gertz¹

¹Division of Hematology, Mayo Clinic, Rochester, MN.

Blood neoplasia

|June 2, 2025

概括

添加达拉图穆马布到环胺,博尔特佐米布和德克萨美沙 (Dara-CyBorD) 显著改善了轻链粉样化症患者的治疗结果,包括与单独使用CyBorD相比,更好的反应和生存率.

科学领域:

血液学血液学血液学
在瘤学瘤学.
临床医学临床医学

背景情况:

轻链 (AL) 氨基粉症是一种罕见的血细胞疾病.
前线治疗旨在实现深度血液学和器官反应.
环胺,博特佐米布和德克萨米松 (CyBorD) 是一种标准的前线治疗方案.

研究的目的:

在现实环境中验证达拉图穆马布加CyBorD (Dara-CyBorD) 的疗效.
为了比较Dara-CyBorD和CyBorD之间的血液学和器官反应率.
评估对无事件生存 (EFS) 和整体生存 (OS) 的影响.

主要方法:

对361名新诊断的AL粉样化症患者 (2018-2022) 的回顾性研究.
与Dara-CyBorD (n=147) 和CyBorD (n=214) 治疗的患者的比较.
对关键结果终点的分析,包括应答率,二线治疗的需要,心脏应答,死亡率,EFS和OS.

主要成果:

达拉-CyBorD在2个月后显示出明显更高的血液学反应率 (60.8%vs31.1%) 和2个月和6个月后的完整反应 (15.3%vs3.0%和39.5%vs17.8%).
较少的Dara-CyBorD患者需要二线治疗 (14.9% vs 42.9%在12个月).
达拉-CyBorD显示出优异的心脏反应,降低6个月死亡率 (8.8% vs 16.3%),改善EFS和OS,特别是在心脏病II期患者中.

结论:

在前线CyBorD中添加达拉图马布显著增强了AL氨基粉症的血液和器官反应.
与单独使用CyBorD相比,Dara-CyBorD降低了早期死亡率,并改善了无事件和整体生存率.
这些发现支持Dara-CyBorD作为AL氨基粉症的有效一线治疗方法.

更多相关视频

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...